Results 141 to 150 of about 10,598 (216)

Pan-TRK expression and NTRK gene aberrations in meningiomas: association with tumor grade and proliferative activity. [PDF]

J Pathol Clin Res
Zhu Y, Sun M, Lu W, Wang Z, Xi H, Song Y, Xu H, Lin X.   +7 more
europepmc   +1 more source

MMR-deficiency and BRCA2/EGFR/NTRK mutations

Aging, 2017
Gokare, Prashanth, Lulla, Amriti R., El-Deiry, Wafik S.   +2 more
openaire   +2 more sources

High-Grade Endometrial Stromal Sarcoma with <i>NTRK</i> Fusion and Response to Larotrectinib: A Case Report. [PDF]

J Clin Med
Bar-Noy T, Lozano-Franco R, Nagaria TS, Brodeur MN, Salvador S, Lau S.   +5 more
europepmc   +1 more source

TRK immunohistochemistry in pediatric rhabdomyosarcomas: diagnostic and prognostic utility and limitations. [PDF]

Pathol Oncol Res
Lajti R, Dezső K, Sápi Z, Papp G, Mohás A, Bukovszky B, Szabó S, Felkai L, Csóka M.   +8 more
europepmc   +1 more source

Distinct molecular profiles of indeterminate and malignant thyroid nodules in patients under 21 years of age. [PDF]

Endocr Relat Cancer
Ricarte-Filho JC, Castellanos L, Waguespack SG, Bryan J, Alshalalfa M, Cavazos TB, Chen Y, Bauer A, Klopper JP, Kloos RT, Franco AT.   +10 more
europepmc   +1 more source

Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study. [PDF]

Exp Hematol Oncol
Zhou S, Zhang C, Wang G, Qian J, Huang G, Wang J, Luo S, Zhu Y, Zhang Q, Wei T, Li Y, Li Z, Zhu D, Zhao H, Fang M, Zhou S, Xu Q, Chen Y, Nan K, Cui J, Zhu X, Gong Y, Wu Y, Lai X, Shi Y.   +24 more
europepmc   +1 more source

Depletion of CARM1 slows in vivo tumorigenicity and rewires developmental programming in glioma stem-like cells. [PDF]

Cell Rep
Young DL, Stransky S, Molero MG, Yamashita E, Pande S, Kumar V, Singh S, Aguilan J, Cutler R, Koba W, DeAngelo JD, Roth JS, Zhang J, He T, Malachowska B, Vercellino J, Bell BI, Shechter D, Tofilon PJ, Phillips RE, Behnan J, Guha C, Sidoli S.   +22 more
europepmc   +1 more source

Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab. [PDF]

ESMO Gastrointest Oncol
Martínez Lago N, Sánchez Ares M, Carral Maseda A, Pérez Martelo M, Covela Rúa M, Fernández Montes A, de la Cámara Gómez J, González Villarroel P, Reboredo López M, Padín Iruegas ME, Abdulkader Nallib I.   +10 more
europepmc   +1 more source

Activating NTRK Family Point Mutation [PDF]

, 2020
openaire   +1 more source

Radioiodine-Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy. [PDF]

Cancer Innov
Li Y, He Z.
europepmc   +1 more source